A5007148032- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Hepatitis C virus research
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Liver Disease Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Immunodeficiency and Autoimmune Disorders
- Acute Lymphoblastic Leukemia research
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- PARP inhibition in cancer therapy
- Hematopoietic Stem Cell Transplantation
- Neuroendocrine Tumor Research Advances
- Viral-associated cancers and disorders
- Peptidase Inhibition and Analysis
- Histone Deacetylase Inhibitors Research
- Virus-based gene therapy research
Mayo Clinic in Arizona
2005-2025
Mayo Clinic in Florida
2002-2025
Mayo Clinic
2007-2024
WinnMed
2003-2024
Dana-Farber Cancer Institute
2024
Boston Medical Center
2024
Constellation Pharmaceuticals (United States)
2024
The Ohio State University
2011-2022
Cancer Research And Biostatistics
2001-2022
Alliance Data (United States)
2017-2022
Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted phase 3 trial to determine whether the addition of midostaurin - an oral multitargeted kinase inhibitor that is active in patients standard chemotherapy would prolong overall survival this population.We screened 3277 patients, 18 59 years age, who had newly diagnosed AML for mutations. were randomly assigned receive (induction therapy daunorubicin cytarabine consolidation high-dose cytarabine)...
Multiple myeloma is a malignancy of plasma cells and characterized by increased marrow angiogenesis. Thalidomide, an agent with antiangiogenic properties, effective in relapsed myeloma. We report the results study combining thalidomide dexamethasone as initial therapy for myeloma.Fifty patients newly diagnosed were studied. Thalidomide was given at dose 200 mg/d orally. Dexamethasone 40 orally on days 1 to 4, 9 12, 17 20 (odd cycles) 4 (even cycles), repeated monthly.Of all 50 patients,...
Mantle cell lymphoma (MCL) is characterized by a t(11;14) resulting in overexpression of cyclin D1 messenger RNA. This study tested whether temsirolimus (previously known as CCI-779), an inhibitor the mammalian target rapamycin kinase that regulates translation, could produce tumor responses patients with MCL.Patients relapsed or refractory MCL were eligible to receive 250 mg intravenously every week single agent. Patients response after six cycles continue drug for total 12 two complete...
A phase II clinical trial with single-agent decitabine was conducted in older patients (≥60 years) previously untreated acute myeloid leukemia (AML) who were not candidates for or refused intensive chemotherapy. Subjects received low-dose at 20 mg/m 2 i.v. over 1 h on days to 10. Fifty-three subjects enrolled a median age of 74 years (range, 60–85). Nineteen (36%) had antecedent hematologic disorder therapy-related AML; 16 complex karyotypes (≥3 abnormalities). The complete remission rate...
Castleman's disease (CD) is a rare, poorly understood lymphoproliferative disease. The spectrum of symptoms and course are broad, but there no large study describing the natural history this Basic clinic laboratory data from records 113 patients with CD evaluated at Mayo Clinic University Nebraska were abstracted. impact these variables on overall survival (OS) time diagnosis was evaluated. Sixty had multicentric Of CD, 32% criteria sufficient for POEMS syndrome. For all patients, 2, 5,...
Retrospective studies suggest cytogenetic abnormalities detected by interphase fluorescent in situ hybridization (FISH) can identify patients with chronic lymphocytic leukemia (CLL) who will experience a more aggressive disease course. Other that may acquire chromosome during the course of their disease. There are minimal prospective data on clinical utility widely used hierarchical FISH prognostic categories newly diagnosed early-stage CLL or frequency clonal evolution as determined...
Purpose: The North Central Cancer Treatment Group performed a phase III trial to determine whether chemotherapy plus either bid radiation therapy (RT) or daily (qd) RT resulted in better outcome for patients with stage non–small-cell lung cancer (NSCLC). No difference survival was identified between the two arms. This secondary analysis examine relationship patient age and outcome. Patients Methods: Two hundred forty-six were randomized receive etoposide cisplatin qd split-course bid....
This phase II study was undertaken to define the efficacy and pharmacodynamics of R115777, a farnesyl transferase inhibitor, in first-line treatment patients with advanced non-small-cell lung cancer.Forty-four measurable stage IIIB (pleural effusion) or IV disease received 193 courses (median, 2.0; range, 1 22) R115777 300 mg administered orally twice daily for 21 every 28 days. Buccal mucosa samples peripheral blood mononuclear cells (PBMCs) were collected before after 8 days evaluate...
Recent reports suggest that the expression of germline (GL) Ig variable region heavy‐chain genes (V H ) is a negative prognostic factor for B‐cell chronic lymphocytic leukaemia (B‐CLL) patients and CLL CD38 may be surrogate marker V gene status. Currently, however, usefulness this controversial. Therefore, our goal was to study ability act as somatic mutation (SM), identify differences in overall survival (OS), progression‐free (PFS) response B‐CLL based on these two markers. We first...
Patients with newly diagnosed, advanced-stage, follicular grade 1 non-Hodgkin's lymphoma (NHL) are often asymptomatic and can be observed without immediate chemotherapy. The goals of this study were to assess the overall response rate (ORR) rituximab in patient population determine time-to-progression (TTP) time-to-subsequent-chemotherapy (TTSC).Eligible patients had untreated NHL, measurable stage III/IV disease. received 375 mg/m(2) intravenous weekly x 4 doses then followed for...
The prevalence of chronic lymphocytic leukemia (CLL) increases with age. Although chemoimmunotherapy (CIT) has dramatically improved response rates in patients CLL, some CIT regimens are not well tolerated by many >or=70 years age.Sixty-four previously untreated CLL and serum creatinine <1.5 times the upper limit normal who met National Cancer Institute (NCI) 96-WG criteria for treatment received pentostatin (2 mg/m(2)), cyclophosphamide (600 rituximab (375 mg/m(2)). authors measured...
Summary In vitro studies have demonstrated that surface expression of CD49d on chronic lymphocytic leukaemia (CLL) B cells facilitates leukaemic cell–stromal interactions by binding to fibronectin. This interaction reduces both spontaneous and drug‐induced apoptosis. The present study measured flow cytometry in a cohort untreated CLL patients previously accrued prospective observational evaluated the relationship with overall survival (OS). Among 158 tested, percentage expressing ranged from...
To prospectively evaluate relationships among serum cytokine levels, innate immune responsiveness, and mortality in a multicenter cohort of critically ill children with influenza infection.Prospective, multicenter, observational study.Fifteen pediatric ICUs members the Pediatric Acute Lung Injury Sepsis Investigators network.Patients ≤18 yrs old admitted to PICU community-acquired infection. A control group outpatient was also evaluated.ICU patients underwent sampling within 72 hrs ICU...
Purpose Sorafenib and lenvatinib are oral multikinase inhibitors targeting vascular endothelial growth factor receptor (VEGFR) approved for radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). However, there no second- or third-line therapies. MET is implicated in resistance to VEGFR inhibitors. Cabozantinib an inhibitor addition medullary cancer. In a phase I study of cabozantinib, five eight patients with DTC previously treated VEGFR-targeted therapy had objective response...